TQB-2618 is under clinical development by Chia Tai Tianqing Pharmaceutical Group and currently in Phase I for Myelodysplastic Syndrome. According to GlobalData, Phase I drugs for Myelodysplastic Syndrome have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how TQB-2618’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
TQB-2618 is under development for the treatment of advanced solid tumors relapsed and refractory acute myeloid leukemia, Hodgkin lymphoma (cHL), B lymphocyte non-Hodgkin lymphoma (B-NHL), T lymphocyte non-Hodgkin lymphoma (T-NHL), advanced melanoma, small-cell lung cancer, non-small cell lung cancer, squamous non-small cell lung cancer, recurrent head and neck squamous cell carcinoma, oropharyngeal cancer, oral cavity cancer, hypopharyngeal cancer, or laryngeal cancer, esophageal squamous cell carcinoma, hepatocellular carcinoma and myelodysplastic syndrome. It is a monoclonal antibody. It is administered through Intravenous and parenteral route. The therapeutic candidate acts by targeting T-cell immunoglobulin mucin domain 3 (TIM-3).
Chia Tai Tianqing Pharmaceutical Group overview
Chia Tai Tianqing Pharmaceutical Group (CTTQ) manufactures and commercializes anticancer drugs. The company produces dosage forms such as freeze-dried powder, large and small volume injections, hard capsules, sheet pills, granules, powders, soft capsules, pills, ointments, creams, pastes, gels, transdermal patches and herbal extracts, and others. It conducts research activities in the areas of anti-tumor, engineering novel liver, cardiovascular, cancer, mental, anesthesia, urinary, and others. The company operates through its technology and research and development centers in Jiangsu. CTTQ is headquartered in Lianyungang, Nanjing, China.
For a complete picture of TQB-2618’s drug-specific PTSR and LoA scores, buy the report here.